help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matsumoto, T.
Right arrow Articles by Rosenfeld, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matsumoto, T.
Right arrow Articles by Rosenfeld, R. G.

Journal of Clinical Endocrinology & Metabolism, Vol 81, 150-155, Copyright © 1996 by Endocrine Society


ARTICLES

Identification and characterization of insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and IGFBP proteases in human synovial fluid

T Matsumoto, SE Gargosky, K Iwasaki and RG Rosenfeld
Department of Pediatrics, Oregon Health Sciences University, Portland, 97201, USA.

The insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) in human synovial fluid play an important role in maintaining articular cartilage metabolism. In this study we measured the concentrations of IGF-I, IGF-II, and IGFBP-3 in normal human synovial fluid by RIA and characterized the IGFBPs by Western ligand blot (WLB), Western immunoblot, and immunoprecipitation. We also extended the study and compared normal synovial fluid to synovial fluids from patients with osteoarthritis (OA) and rheumatoid arthritis (RA). The concentrations of IGF-I, IGF-II, and IGFBP-3 in normal synovial fluid were 19 +/- 3 (mean +/- SE), 194 +/- 14, and 349 +/- 65 ng/mL, respectively. In synovial fluid of patients with OA, IGF-I levels were elevated, whereas IGF-II was decreased, and the IGFBP-3 level was similar to the control value. In patients with RA, both IGF-I and IGFBP- 3 were elevated, whereas IGF-II remained unchanged. WLB and immunoprecipitation of normal synovial fluid revealed IGFBP-1 (26-29 kDa), IGFBP-2 (32 kDa), IGFBP-3 (42- to 39-kDa doublet), and IGFBP-4 (24 kDa); the IGFBP-3 doublet was very faint. In RA synovial fluid, all IGFBPs were dramatically increased, whereas little change was seen in the synovial fluid of OA. Western immunoblot against IGFBP-3 revealed a prominent 30-kDa immunoreactive fragment of IGFBP-3 in synovial fluids of normal adults as well as in those of RA and OA patients. This was concurrent with detectable IGFBP-3 protease activity, which was characterized to be of the metallo- and serine protease family. Thus, in normal synovial fluid, there is a balance of circulating IGF, IGFBP, and proteases to modulate the bioactivity of IGF. In pathological states, the increased IGF-I concentrations were accompanied by an increase in IGFBP-I concentrations were accompanied by an increase in IGFBP-3 levels in synovial fluid. These findings suggest that alteration of the IGF and IGFBP axis in pathological states may be important for understanding the underlying pathophysiology of disordered articular growth and metabolism.


This article has been cited by other articles:


Home page
J EndocrinolHome page
E. Himpe, C. Degaillier, A. Coppens, and R. Kooijman
Insulin-like growth factor-1 delays Fas-mediated apoptosis in human neutrophils through the phosphatidylinositol-3 kinase pathway
J. Endocrinol., October 1, 2008; 199(1): 69 - 80.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
T. Matsumoto and T. Tsurumoto
Inappropriate serum levels of IGF-I and IGFBP-3 in patients with rheumatoid arthritis
Rheumatology, March 1, 2002; 41(3): 352 - 353.
[Full Text] [PDF]


Home page
EndocrinologyHome page
Y. Dubaquie, D. L. Mortensen, A. Intintoli, D. A. Hogue, G. Nakamura, P. Rancatore, P. Lester, M. D. Sadick, E. Filvaroff, P. J. Fielder, et al.
Binding Protein-3-Selective Insulin-Like Growth Factor I Variants: Engineering, Biodistributions, and Clearance
Endocrinology, January 1, 2001; 142(1): 165 - 173.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
V. C. Russo, G. Rekaris, N. L. Baker, L. A. Bach, and G. A. Werther
Basic Fibroblast Growth Factor Induces Proteolysis of Secreted and Cell Membrane-Associated Insulin-Like Growth Factor Binding Protein-2 in Human Neuroblastoma Cells
Endocrinology, July 1, 1999; 140(7): 3082 - 3090.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
D. Sunic, J. D. McNeil, T. E. Rayner, D. L. Andress, and D. A. Belford
Regulation of Insulin-Like Growth Factor-Binding Protein-5 by Insulin-Like Growth Factor I and Interleukin-1{alpha} in Ovine Articular Chondrocytes
Endocrinology, May 1, 1998; 139(5): 2356 - 2362.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
S. Rajaram, D. J. Baylink, and S. Mohan
Insulin-Like Growth Factor-Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions
Endocr. Rev., December 1, 1997; 18(6): 801 - 831.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
A. Spagnoli, V. Hwa, W. A. Horton, G. P. Lunstrum, C. T. Roberts Jr., F. Chiarelli, M. Torello, and R. G. Rosenfeld
Antiproliferative Effects of Insulin-like Growth Factor-binding Protein-3 in Mesenchymal Chondrogenic Cell Line RCJ3.1C5.18. RELATIONSHIP TO DIFFERENTIATION STAGE
J. Biol. Chem., February 16, 2001; 276(8): 5533 - 5540.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1996 by The Endocrine Society